BESTAGEING
Biomarker Research Alliance for Diagnosing Heart Disease in the Ageing European Population
| Coordinatore | UNIVERSITAETSKLINIKUM HEIDELBERG
Organization address
address: IM NEUENHEIMER FELD 672 contact info |
| Nazionalità Coordinatore | Germany [DE] |
| Totale costo | 15˙184˙316 € |
| EC contributo | 10˙906˙368 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2012-INNOVATION-1 |
| Funding Scheme | CP-IP |
| Anno di inizio | 2013 |
| Periodo (anno-mese-giorno) | 2013-02-01 - 2017-01-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
UNIVERSITAETSKLINIKUM HEIDELBERG
Organization address
address: IM NEUENHEIMER FELD 672 contact info |
DE (HEIDELBERG) | coordinator | 1˙730˙400.00 |
| 2 |
COMPREHENSIVE BIOMARKER CENTER GMBH
Organization address
address: IM NEUENHEIMER FELD 519 contact info |
DE (HEIDELBERG) | participant | 1˙872˙492.00 |
| 3 |
ACS BIOMARKER BV
Organization address
address: OXFORDLAAN 70 contact info |
NL (MAASTRICHT) | participant | 1˙391˙200.00 |
| 4 |
METANOMICS GMBH
Organization address
address: TEGELER WEG 33 contact info |
DE (BERLIN) | participant | 783˙600.00 |
| 5 |
SIEMENS AKTIENGESELLSCHAFT
Organization address
address: Wittelsbacherplatz 2 contact info |
DE (MUNCHEN) | participant | 683˙576.00 |
| 6 |
Academisch Medisch Centrum bij de Universiteit van Amsterdam
Organization address
address: MEIBERGDREEF 9 contact info |
NL (AMSTERDAM) | participant | 534˙400.00 |
| 7 |
TARTU ULIKOOL
Organization address
address: ULIKOOLI 18 contact info |
EE (TARTU) | participant | 531˙400.00 |
| 8 |
UNIVERSITAET DES SAARLANDES
Organization address
address: CAMPUS contact info |
DE (SAARBRUECKEN) | participant | 453˙600.00 |
| 9 |
UPPSALA UNIVERSITET
Organization address
address: SANKT OLOFSGATAN 10 B contact info |
SE (UPPSALA) | participant | 420˙400.00 |
| 10 |
MULTIPLICOM NV
Organization address
address: GALILEILAAN 18 contact info |
BE (NIEL) | participant | 402˙400.00 |
| 11 |
JOHANN WOLFGANG GOETHE UNIVERSITAET FRANKFURT AM MAIN
Organization address
address: GRUNEBURGPLATZ 1 contact info |
DE (FRANKFURT AM MAIN) | participant | 396˙400.00 |
| 12 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | participant | 366˙400.00 |
| 13 |
Health in Code SL
Organization address
city: A CORUNA contact info |
ES (A CORUNA) | participant | 295˙200.00 |
| 14 |
UNIVERSITA DEGLI STUDI DI PADOVA
Organization address
address: VIA 8 FEBBRAIO 2 contact info |
IT (PADOVA) | participant | 288˙000.00 |
| 15 |
NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS
Organization address
address: CHRISTOU LADA 6 contact info |
EL (ATHENS) | participant | 162˙000.00 |
| 16 |
STATE INSTITUTION NATIONAL SCIENTIFIC CENTER INSTITUTE OF CARDIOLOGY NAMED AFTER ACADEMICIAN M. D. STRAZHESKO NATIONAL ACADEMY MEDICAL SCIENCES OF UKRAINE
Organization address
address: NARODNOGO OPOLCHENIA STREET 5 contact info |
UA (KYIV) | participant | 156˙000.00 |
| 17 |
AZIENDA COMPLESSO OSPEDALIERO SAN FILIPPO NERI*
Organization address
address: PIAZZA S MARIA DELLA PIETA 5 contact info |
IT (ROMA) | participant | 154˙500.00 |
| 18 |
UNIVERSITA CATTOLICA DEL SACRO CUORE
Organization address
address: Largo Agostino Gemelli 1 contact info |
IT (MILANO) | participant | 144˙000.00 |
| 19 |
SERVICIO MADRILENO DE SALUD
Organization address
address: PLAZA CARLOS TRIAS BERTRAN 7 contact info |
ES (MADRID) | participant | 140˙400.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The ageing of the European population represents a rapidly rising social and economic challenge. Especially cardiovascular morbidity increases with age, but unfortunately, elderly patients are often difficult to diagnose due to confounding factors, leading to uncertainties in clinical decision making with huge impact on patients’ outcomes. Hence, there is an unmet need for novel biomarkers for more accurate diagnosis, risk assessment, and clinical outcome prediction for both acute and chronic cardiovascular diseases in the elderly. The BestAgeing consortium aims to improve this lack of diagnostic capabilities by developing and validating innovative omics-based biomarkers particularly for elderly patients – supporting healthy ageing in Europe. Our study design addresses the most frequent and severe cardiovascular diseases of elderly patients by incorporating the appropriate disease cohorts and biomaterials from European populations. We aim to develop new omics-assays to diagnose cardiovascular disease, estimate risk, and monitor the response to treatment in elderly. This is envisaged to enable a more stratified and economic delivery of medicine. We expect that BestAgeing will generate novel European medical technologies that can improve the efficacy and efficiency of our care for elderly patients, which will also impact on socioeconomic wealth in Europe.'
Descrizione progetto (Article)
Already due to remarkable progress in prevention and acute cardiac patient care, cardiovascular diseases now show up significantly later in life. However, when heart disease develops later it is often complicated and hidden by other diseases. The project 'Biomarker research alliance for diagnosing heart disease in the ageing European population' (http://www.bestageing.eu/home.htm (BESTAGEING)) is working on finding new, specific and sensitive biomarkers for diagnosis, risk prediction and treatment guidance. These new guidelines will help to accurately predict for acute and chronic cardiovascular diseases in the elderly who have other health issues.
The project's strategy capitalises on extensive previous work on established biomarkers and new markers of coronary artery disease, myocardial infarction and heart failure. Expertise in assay and technology development, experience in analytical and clinical validation, and the abilities of the researchers will translate into marketable solutions of the findings.
Preparatory work for the retrospective and prospective validation studies has been completed. The table of omics-based biomarkers for validation was updated with some additional markers of interest, and the definition of the clinical phenotypes addressed in BESTAGEING was refined. This phenotype characterisation is of major importance because the clinical phenotype must be very precise yet applicable for different clinical centres, for retrospective and prospective studies.
Researchers are testing the cost effectiveness of novel biomarkers on European health care systems and economics. Using relevant national and international data sources and economic measures of diagnostic and therapeutic procedures, activities continue for public outreach, communicating scientific work and the results of biomarker development.
Ultimately, successful validation and translation into clinical application of new biomarkers is expected to strongly and beneficially impact the European population and economy. This will mean reduced health care costs, and increased quality of life and healthy years.